Disparate effects of 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid in vascular endothelial and smooth muscle cells and in cardiomyocytes

Archives of Physiology and Biochemistry

Volumn 112, Issue 2, 2006, Pages 119-129

  Sasson, Shlomo ^a   Eckel, J ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Cardiomyocytes; Diabetes; Endothelial cells; Hydroxyeicosatetraenoic acid; Hyperglycaemia; Lipoxygenase; Smooth muscle cells; Vascular disease

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 12 LIPOXYGENASE; GLUCOSE TRANSPORTER 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

CARDIOVASCULAR DISEASE; CELL INTERACTION; CONFERENCE PAPER; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT SYSTEM; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; SMOOTH MUSCLE FIBER;

ARACHIDONATE 12-LIPOXYGENASE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HYDROXYEICOSATETRAENOIC ACIDS; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC;

ANIMALIA;

EID: 33748640374     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450600712035     Document Type: Conference Paper

References (100)

1. Alpert E, Gruzman A, Totary H, Kaiser N, Reich R, Sasson S. 2002. A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: role of glucose and 12-hydroxyeicosatetraenoic acid. Biochem J 362:413-22.
2. Alpert E, Gruzman A, Riahi Y, Blejter R, Aharoni P, Weisinger J, Eckel J, Sasson S. 2005. Delayed autoregulation of glucose transport in vascular endothelial cells. Diabetologia 48:752-5.
3. Aronson D, Rayfield EJ. 2002. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 1:1.
4. 2 in high glucose medium. Diabetes 44:520-6.
5. Basu S. 2004. Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic Res 38:105-22.
6. Beckman JA, Creager MA, Libby P. 2002. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 28:2570-81.
7. Bell DS. 2003. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26:2433-41.
8. Bleich D, Chen S, Zipser B, Sun D, Funk CD, Nadler JL. 1999. Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. J Clin Invest 103:1431-6.
9. Bloomgarden ZT. 1997. Topics in cardiovascular disease and diabetes. Diabetes Care 20:1624-7.
10. Bowman L, Armitage J. 2002. Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular risk. Semin Vasc Med 2:383-9.
11. Breitbart E, Sofer Y, Shainberg A, Grossman S. 1996. Lipoxygenase activity in heart cells. FEBS Lett 395:148-52.
12. Brownlee M. 1992. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15:1835-43.
13. Brownlee M. 2000. Negative consequences of glycation. Metabolism 4:9-13.
14. Caballero AE. 2005. Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch Med Res 36:241-9.
15. Caijo F, Mosset P, Gree R, Audinot-Bouchez V, Boutin J, Renard P, Caignard DH, Dacquet C. 2005. Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs. Bioorg Med Chem Lett 15:4421-6.
16. Candido R, Srivastava P, Cooper ME, Burrell LM. 2003. Diabetes mellitus: a cardiovascular disease. Curr Opin Investig Drugs 4:1088-94.
17. Cook JA. 2005. Eicosanoids. Crit Care Med 33:S488-91.
18. Daneman D. 2005. Early diabetes-related complications in adolescents: risk factors and screening. Horm Res 63:75-85.
19. Dransfeld O, Rakatzi I, Sasson SAG, Scmitt M, Haussinger D, Eckel J. 2001. Eicosanoids participate in the regulation of cardiac glucose transport by contribution to a rearrangement of actin cytoskeletal elements. Biochem J 359:47-54.
20. Dransfeld O, Rakatzi I, Sasson S, Eckel J. 2002. Eicosanoids and the regulation of cardiac glucose transport. Ann NY Acad Sci 967:208-16.
21. Du K, Stockklauser-Färber K, Rösen P. 1999. Generation of reactive oxygen intermediates, activation of NF-kB, and induction of apoptosis in human endothelial cells by glucose: Role of nitric oxide synthase? Free Radic Biol Med 27:752-63.
22. Eckel J. 2001. Glucose transport in heart: Special emphasis on insulin resistance and NIDDM. In: Zierath JR, Wallberg-Henriksson H, editors, Frontiers in Animal Diabetes Research: Muscle Metabolism. London: Taylor & Francis; pp 313-27.
23. Eckel J, Wirdeier A, Herberg L, Reinauer H. 1985. Insulin resistance in the heart: studies on isolated cardiocytes of genetically obese Zucker rats. Endocrinology 116:1529-34.
24. Eckel J, Rohn G, Kiesel U, Reinauer H. 1987. Insulin binding and action in isolated cardiocytes from spontaneously diabetic BB rats. Diabetes Res 4:79-83.
25. Factor SM, Borczuk A, Charron MJ, Fein FS, van Hoeven KH, Sonnenblick EH. 1996. Myocardial alterations in diabetes and hypertension. Diabetes Res Clin Pract 31 (Suppl.):S133-42.
26. Fang X, Hu S, Xu B, Snyder GD, Harmon S, Yao J, Liu Y, Sangras B, Falck JR, Weintraub NL, Spector AA. 2006. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferatoractivated receptor-alpha. Am J Physiol Heart Circ Physiol 290: H55-63.
27. Fonarow GC. 2005. An approach to heart failure and diabetes mellitus. Am J Cardiol 96:47E-52E.
28. Garvey WT,Harfin D, JuhaszovaM,Dominguez JH. 1993. Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. AmJ Physiol 264:H837-44.
29. Goldberg RB. 2003. Cardiovascular disease in patients who have diabetes. Cardiol Clin 21:399-413.
30. Gu JL, Pei H, Thomas L, Nadler JL, Rossi JJ, Lanting L, Natarajan R. 2001. Ribozyme-mediated inhibition of rat leukocyte-type 12-lipoxygenase prevents intimal hyperplasia in balloon-injured rat carotid arteries. Circulation 103:1446-52.
31. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. 2002. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105:1656-62.
32. Hedrick CC, Kim MD, Natarajan RD, Nadler JL. 1999. 12-Lipoxygenase products increase monocyte:endothelial interactions. Adv Exp Med Biol 469:455-60.
33. Honda HM, Leitinger N, Frankel M, Goldhaber JI, Natarajan R, Nadler JL, Weiss JN, Berliner JA. 1999. Induction of monocyte binding to endothelial cells by MM-LDL: role of lipoxygenase metabolites. Arterioscler Thromb Vasc Biol 19:680-6.
34. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, Glass CK. 1999. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400:378-82.
35. Hunt JV, Dean RT, Wolff SP. 1988. Hydroxyl radical production and autooxidative glycosylation. Glucose autooxidation as a cause of protein damage in the experimental glycation model of diabetes mellitus and aging. Biochem J 256:205-12.
36. Huo Y, Zhao L, Hyman MC, Shashkin P, Harry BL, Burcin T, Forlow SB, Stark MA, Smith DF, Clarke S, Srinivasan S, Hedrick CC, Pratico D, Witztum JL, Nadler JL, Funk CD, Ley K. 2004. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation 110:2024-31.
37. Joshua IG, Zhang Q, Falcone JC, Bratcher AP, Rodriguez WE, Tyagi SC. 2005. Mechanisms of endothelial dysfunction with development of type 1 diabetes mellitus: role of insulin and C-peptide. J Cell Biochem 96:1149-56.
38. Kainulainen H, Breiner M, Schurmann A, Marttinen A, Virjo A, Joost HG. 1994. In vivo glucose uptake and glucose transporter proteins GLUT1 and GLUT4 in heart and various types of skeletal muscle from streptozotocin-diabetic rats. Biochim Biophys Acta 1225:275-82.
39. Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, Moller DE, Davidheiser S, Przybylski RJ, King GL. 1993. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42:80-9.
40. Kang LT, Vanderhoek JY. 1998. Mono (S) hydroxy fatty acids: novel ligands for cytosolic actin. J Lipid Res 39:1476-82.
41. Kang LT, Philips TM, Vanderhoek. JY 1999. Novel membrane target proteins for lipoxygenase-derived mono(S)hydroxy fatty acids. Biochim Biophys Acta 1438:388-96.
42. Karvounis HI, Papadopoulos CE, Zaglavara TA, Nouskas IG, Gemitzis KD, Parharidis GE, Louridas GE. 2004. Evidence of left ventricular dysfunction in asymptomatic elderly patients with non-insulin-dependent diabetes mellitus. Angiology 55:549-55.
43. Kendall DM, Harmel AP. 2002. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Am J Manag Care 8:S635-53.
44. Kolter T, Uphues I, Eckel J. 1997. Molecular analysis of insulin resistance in isolated ventricular cardiomyocytes of obese Zucker rats. Am J Physiol 273:E59-67.
45. Lorenzi M, Cagliero E, Toledo S. 1985. Glucose toxicity for human endothelial cells in culture. Delayed replication, disturbed cell cycle, and accelerated death. Diabetes 34:621-7.
46. Marwick TH. 2006. Diabetic heart disease. Heart 92:296-300.
47. Meigs JB. 2003. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta Diabetol 40 (Suppl. 2):S358-61.
48. Miller YI, Chang MK, Funk CD, Feramisco JR, Witztum JL. 2001. 12/15-Lipoxygenase translocation enhances site-specific actin polymerization in macrophages phagocytosing apoptotic cells. J Biol Chem 276:19431-39.
49. Miller YI, Worrall D, Funk CD, Feramisco JR, Witztum JL. 2003. Actin polymerization macrophages in response to oxidized LDL and apoptotic cells: role of 12/15-lipoxygenase and phosphoinositide 3-kinase. Mol Biol Cell 14:4196-206.
50. Milstien S, Katusic Z. 1999. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 263:681-4.
51. Mooradian AD. 2003. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med 16:33-40.
52. Morales DE. 1993. Atherosclerosis. In: Lilly LS, editor, Pathophysiology of Heart Disease. Philadelphia, PA, Lea & Febiger, pp 84-97.
53. Natarajan R, Nadler JL. 2003. Lipoxygenases and lipid signaling in vascular cells in diabetes. Front Biosci 8:s783-95.
54. Natarajan R, Nadler JL. 2004. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 24:1542-8.
55. Natarajan R, Gonzales N, Xu L, Nadler JL. 1992. Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Biochem Biophys Res Commun 187:552-60.
56. Natarajan R, Gu JL, Rossi J, Gonzales N, Lanting L, Xu L, Nadler J. 1993. Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc Natl Acad Sci USA 90:4947-51.
57. Natarajan R, Bai W, Rangarajan V, Gonzales N, Gu JL, Lanting L, Nadler JL. 1996. Platelet-derived growth factor BB mediated regulation of 12-lipoxygenase in porcine aortic smooth muscle cells. J Cell Physiol 169:391-400.
58. Natarajan R, Gerrity RG, Gu JL, Lanting L, Thomas L, Nadler JL. 2002. Role of 12-lipoxygenase and oxidant stress in hyperglycaemia-induced acceleration of atherosclerosis in a diabetic pig model. Diabetologia 45:125-33.
59. Nesto RW. 2004. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 116 (Suppl 5A):11S-22S.
60. Ohtake T, Yokoyama I, Watanabe T, Momose T, Serezawa T, Nishikawa J, Sasaki Y. 1995. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med 36:456-63.
61. Omata W, Shibata H, Takata K, Kojima I. 2000. Actin filaments play a critical role in insulin-induced exocytotic recruitment but not endocytosis of GLUT4 in isolated rat adipocytes. Biochem J 346:321-8.
62. Patricia MK, Kim JA, Harper CM, Shih PT, Berliner JA, Natarajan R, Nadler JL, Hedrick CC. 1999. Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arterioscler Thromb Vasc Biol 19:2615-22.
63. Patricia MK, Natarajan R, Dooley AN, Hernandez F, Gu JL, Berliner JA, Rossi JJ, Nadler JL, Meidell RS, Hedrick CC. 2001. Adenoviral delivery of a leukocyte-type 12-lipoxygenase ribozyme inhibits effects of glucose and platelet-derived growth factor in vascular endothelial and smooth muscle cells. Circ Res 88:659-65.
64. Pei H, Gu J, Thimmalapura PR, Mison A, Nadler JL. 2006. Activation of the 12-lipoxygenase and signal transducer and activator of transcription pathway during neointima formation in a model of the metabolic syndrome. Am J Physiol Endocrinol Metab 290:E92-102.
65. Pickup JC. 2004. Inflammation and activated innate inmmunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813-23.
66. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC, Vazquez-Carrera M. 2005. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 65:832-41.
67. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. 2005. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25:1810-6.
68. Reaven GM, Lithell H, Landsberg L. 1996. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. New Engl J Med 334:374-81.
69. Reddy MA, Adler SG, Kim YS, Lanting L, Rossi J, Kang SW, Nadler JL, Shahed A, Natarajan R. 2002a. Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol 283:F985-94.
70. Reddy MA, Thimmalapura PR, Lanting L, Nadler JL, Fatima S, Natarajan R. 2002b. The oxidized lipid and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cAMP response element-binding protein activation. Mediation of angiotensin II effects. J Biol Chem 277:9920-8.
71. Reilly KB, Srinivasan S, Hatley ME, Patricia MK, Lannigan J, Bolick DT, Vandenhoff G, Pei H, Natarajan R, Nadler JL, Hedrick CC. 2004. 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem 27:9440-50.
72. Rice RL, Tang DG, Haddad M, Honn KV, Taylor JD. 1998. 12(S)hydroxyeicosatetraenoic acid increases the actin micro-filament content in B16a melanoma cells: a protein kinasedependent process. J Int Cancer 77:271-8.
73. Sander GE, Giles TD. 2003. Diabetes mellitus and heart failure. Am Heart Hosp J 1:273-80.
74. Sano T, Umeda F, Hashomoto T, Nawata H, Utsumi H. 1998. Oxidative stress measurements by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia 41:1355-60.
75. Sasson S, Gorowits N, Joost HG, King GL, Cerasi E, Kaiser N. 1996. Regulation by metformin of the hexose transport system in vascular endothelial and smooth muscle cells. Br J Pharmacol 117:1318-24.
76. Schalkwijk CG, Stehouwer CD. 2005. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 109:143-59.
77. Soares AF, Nosjean O, Cozzone D, D'Orazio D, Becchi M, Guichardant M, Ferry G, Boutin JA, Lagarde M, Geloen A. 2005. Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARgamma. Biochem Biophys Res Commun 337:521-5.
78. Sowers JR, Frohlich ED. 2004. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 88:63-82.
79. Stanley WC, Lopaschuk GD, McCormack JG. 1997. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34:25-33.
80. Tang DG, Diglio CA, Honn KV. 1993a. 12(S)-HETE-induced microvascular endothelial cell retraction results from PKC-dependent rearrangement of cytoskeletal elements and alpha V beta 3 integrins. Prostaglandins 45:249-67.
81. Tang DG, Grossi YQ, Chen CA, Diglio CA, Honn KV. 1993b. 12(S)-HETE promotes tumor cell adhesion by increasing surface expression of αVβ3 integrins on endothelial cells. Clin Exp Metastasis 7:127-67.
82. Tang DG, Diglio CA, Honn KV. 1994. Activation of microvascular endothelium by eicosanoids 12(S)-hydroxyeicosatetraenoic acid leads to enhanced tumor cell adhesion via up-regulation of surface expression of alpha V beta 3 integrin. Cancer Res 54:1119-29.
83. Taylor AM, Hanchett R, Natarajan R, Hedrick CC, Forrest S, Nadler JL, McNamara CA. 2005. The effects of leukocytetype 12/15-lipoxygenase on Id3-mediated vascular smooth muscle cell growth. Arterioscler Thromb Vasc Biol 25:2069-74.
84. Tenenbaum A, Motro M, Fisman EZ. 2005. Dual and panperoxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 4:14.
85. Totary-Jain H, Naveh-Many T, Riahi Y, Kaiser N, Eckel J, Sasson S. 2005. Calreticulin destabilizes glucose transporter-1 mRNA in vascular endothelial and smooth muscle cells under high-glucose conditions. Circ Res 97:1001-8.
86. Torok D, Patel N, Jebailey L, Thong FS, Randhawa VK, Rudich A. 2004. Insulin but not PDGF relies on actin remodeling and on VAMP2 for GLUT4 translocation in myoblasts. J Cell Sci 117:5447-55.
87. Tropeano AI, Boutouyrie P, Katsahian S, Laloux B, Laurent S. 2004. Glucose level is a major determinant of carotid intimamedia thickness in patients with hypertension and hyperglycemia. J Hypertens 22:2153-60.
88. Tsakiridis T, Tong P, Matthews B, Tsiani E, Bilan PJ, Klip A, Downey GP. 1999. Role of actin cytoskeleton in insulin action. Microsc Res Tech 47:79 - 92.
89. Vahsen S, Rakowski K, Ledwig D, Dietze-Schroeder D, Swifka J, Sasson S, Eckel J. 2006. Altered GLUT-4 translocation in skeletal muscle of 12/15-lipoxygenase knockout mice. Horm Met Res (In press).
90. Vang K, Ziboh VA. 2005. 15-lipoxygenase metabolites of gammalinolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids. Prostaglandins Leukot Essent Fatty Acids 72:363-72.
91. Varughese GI, Tomson J, Lip GY. 2005. Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract 59:798-816.
92. Voipio-Pulkki LM, Nuutila P, Knuuti MJ, Ruotsalainen U, Haaparanta M, Teras M, Wegelius U, Koivisto VA. 1993. Heart and skeletal muscle glucose disposal in type 2 diabetic patients as determined by positron emission tomography. J Nucl Med 34:2064-7.
93. Watts GF, Marwick TH. 2003. Ventricular dysfunction in early diabetic heart disease: detection, mechanisms and significance. Clin Sci (Lond) 105:537-40.
94. Wen Y, Gu J, Liu Y, Wang PH, Sun Y, Nadler JL. 2001. Overexpression of 12-lipoxygenase causes cardiac fibroblast cell growth. Circ Res 88:70-6.
95. Wolff SP, Dean RT. 1987. Glucose autooxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 245:243-50.
96. Yamagishi S, Imaizumi T. 2005. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279-99.
97. Yki-Jarvinen H. 2000. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs 60:975-83.
98. Yu Y, Lyons TJ. 2005. A lethal tetrad in diabetes: hyperglycemia, dyslipidemia, oxidative stress, and endothelial dysfunction. Am J Med Sci 330:227-32.
99. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA. 1995. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270:23975-83.
100. Ziegler D. 2005. Type 2 diabetes as an inflammatory cardiovascular disorder. Curr Mol Med 5:309-22.